Publication details
Polyneuropatie jako následek protinádorové léčby
| Title in English | Chemotherapy-induced peripheral neuropathy |
|---|---|
| Authors | |
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Onkologická revue |
| MU Faculty or unit | |
| Citation | |
| web | https://onkologickarevue.cz/cs/polyneuropatie-jako-nasledek-protinadorove-lecby |
| Keywords | polyneuropathy; chemotherapy; antineuralgic therapy; platinum derivatives; vinca alkaloids; taxanes |
| Description | Chemotherapy-induced polyneuropathy (CIPN) is a very common side effect of antitumor therapy, which fundamentally affects the quality of life of patients, and may lead to the need for dose reduction or modification of the antitumor therapy schedule. Most patients experience regression or complete resolution of clinical symptoms over time, but in some individuals clinical symptoms may persist over the long term. The most prominent neurotoxic agents include platinum derivatives, taxanes, vinca alcoloids, proteasome complex inhibitors (bortezomib) and thalidomide. In particular, CIPN affects sensitive nerves, and rarely autonomic or motor symptoms such as postural hypotension or muscle weakness are encountered. The development of CIPN can be prevented by the correct indication of neurotoxic treatment. It is particularly appropriate to take into account pre-existing neuropathy or the existence of its risk factors. At the same time, the condition of the peripheral nervous system should be monitored regularly during treatment and, when clinical symptoms occur, reduce neurotoxic therapy or change the treatment regimen. |
| Related projects: |